Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer
Palbociclib was associated with a significantly lower risk of MACE compared with ribociclib in patients with breast cancer. Patients who developed hypertension or MACE incurred substantially higher health care costs. These findings underscore the importance of minimizing CV adverse events in patients with breast cancer treated with CDK4/6 inhibitors.
Authors
- Ahmed S. Kenawy (ORCID: https://orcid.org/0000-0002-5133-265X)
- Yanliang Lin (ORCID: https://orcid.org/0000-0002-1682-3373)
- Yi‐Shao Liu (ORCID: https://orcid.org/0009-0004-6958-3918)
- Chanhyun Park (ORCID: https://orcid.org/0000-0002-1081-0950)
- Ji Haeng Heo (ORCID: https://orcid.org/0000-0001-6196-9366)
- Yan Liu (ORCID: https://orcid.org/0000-0002-9123-4974)
Institutions
- The University of Texas at Austin (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-04-18
- DOI
- https://doi.org/10.6004/jnccn.2025.7001
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 6.07